Peptic Ulcer Drugs Market Report and Forecast 2025-2034

The peptic ulcer drugs market attained a value of USD 6.12 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 3.80%, to reach USD 8.89 Billion by 2034.

Peptic Ulcer Drugs Market Overview

Peptic ulcers are characterized by open sores on the lining of the esophagus, stomach, or small intestine. The most common symptom is pain in the upper abdominal region. It is usually caused by the bacterium Helicobacter pylori and long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin. Peptic ulcers affect 1 out of 12 individuals in the United States with 1 in 5 cases associated with the bacterial infection . The rising prevalence of the disease is one of the key factors driving the peptic ulcer drugs market demand and is anticipated to accelerate the growth of the market in the forecast period.

The surge in drug approvals by the health regulatory bodies is expected to further bolster the market growth. In October 2023, the  United States Food and Drug Administration (FDA) approved reformulated vonoprazan tablets for Voquezna Triple Pak and Voquezna Dual Pak to treat Helicobacter pylori infection in adults. Developed by Phathom Pharmaceuticals, a United States-based biopharmaceutical company, these drugs combine antibiotics with vonoprazan, a novel potassium-competitive acid blocker. This new class of acid suppression therapy offers promising H. pylori eradication rates. The company plans to commercially launch it in December 2023 for H. pylori treatment.

The peptic ulcer drugs market share is also expected to experience a significant expansion due to increasing research and development activities backed by robust support from the government. Moreover, the growing geriatric population and advancement in the healthcare system will also boost the market growth.

Peptic Ulcer Drugs Market Segmentation

Peptic Ulcer Drugs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

• Proton Pump Inhibitor
• H2 Antagonist
• Antibiotics
• Antacids
• Ulcer Protective

Based on the product type, the market covers various therapeutics used in the treatment and management of peptic ulcers. These include proton pump inhibitors, H2 antagonists, antibiotics, antacids, and ulcer protective.

Market Breakup by Disease Indication

• Gastritis
• Gastric Ulcer
• Duodenal Ulcer
• GERD
• Others

The peptic ulcer drugs market is divided by disease indication, which includes gastritis, gastric ulcer, duodenal ulcer, and GERD, among others. This segmentation represents the various conditions for which peptic ulcer drugs are prescribed.

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Peptic ulcer drugs are distributed to the users through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, among others. Each distribution channel offers unique advantages and conveniences for patients seeking access to peptic ulcer medications.

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

The report covers 8 major markets poised to witness significant peptic ulcer drugs market growth in upcoming years. It is divided into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market for peptic ulcer drugs which can be attributed to the rising cases of the disease, along with the growing healthcare expenditure in the region.

Peptic Ulcer Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Orion Corporation
• Bausch Health Companies Inc.
• CYTOKINETICS, INC.
• Aquestive Therapeutics, Inc.
• Sanofi
• Covis Pharma
• Sun Pharmaceuticals Industries Ltd
• Mitsubishi Tanabe Pharma Corporation
• BrainStorm Cell Limited
• ViroMed Co., Ltd
• Ionis Pharmaceuticals
• Genervon Biopharmaceuticals, LLC
• Biogen
• Orphazyme A/S
• F. Hoffmann-La Roche Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Queries Solved in the Peptic Ulcer Drugs Market Report

• How is the market landscape expected to evolve in coming years?
• What are the major market trends influencing the market?
• What are the major drivers, opportunities, and restraints in the market?
• What will be the effect of each driver, challenge, and opportunity on the market?
• Which country is poised to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What factors contribute to the rising peptic ulcers market demand?
• What is the incidence and epidemiology of peptic ulcers?
• What are the different types of peptic ulcer drugs available in the market?
• What are the latest advancements in peptic ulcer drug research and development, including novel drug candidates and formulations?
• Which drugs are under clinical trials?
• What were the major drug approvals used to manage peptic ulcers during the historical period?
• Which major drug manufacturers are expected to lead the market?
• What are the key strategies adopted by leading pharmaceutical companies to gain market share?
• How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics of peptic ulcer drugs?